Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1] »

[at noodls] – Study published in NEJM today and presented tomorrow met primary endpoint[1] in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizumab patients … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view